BIOL 409 - Molecular Biology
Extra Credit - Herceptin
Herceptin is also known as Trastuzumab, made by Genentech. It is a medication that is used to treat breast cancer. It interferes with the HER2/neureceptor. The HER proteins regulate cell growth, survival, adhesion, migration, and differentiation. Such function of the protein are usually amplified or weakened in cancer cells. In Breast Cancer, HER2 is over-expressed, which leads to breast cells to reproduce uncontrollably. But Herceptin binds to the HER2 proteins causing the HER2 to no longer cause cancer cells of the breast to reproduce uncontrollably. This drug is in the class of Monoclonal antibodies. The HER2 pathway promotes cell growth and division in the active state. There are checkpoints that regulate this process. During cancer, this pathway is stimulated to promote cell growth and proliferation rapidly. The HER2 protein is involved in the EGF pathway which functions as ligand binding and heterodimerization. This pathway leads to activation of the MAP kinase pathway and PI3 kinase/AKT pathway which leads to activation of NF-Kinase B pathway. This in some cases leads to overexpression of HER2 causing deactivation of the checkpoints.
This research paper “Insulin- Like Growth Factors-I receptor signaling and resistance to Trastuzumab (Herceptin). This research article is about finding out how resistance to Trastuzumab is developed. A hypothesis is made and investigated that insulin-like growth factor-I interfere with growth inhibitory process of the Trastuzumab. Insulin-Like Growth Factor-I activates cell survival signaling pathways. After experimentation, it was found that only an increased level of IGF-I, when HER2 proteins were overexpressed, interferes with the action of Trastuzumab.
Yuhong Lu, Xiaolin Zi, Yunhua Zhao, Desmond Mascarenhas, and Michael Pollak. Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin) JNCI J Natl Cancer Inst...
Please join StudyMode to read the full document